[Source: www.bseindia.com ]
Lupin Limited announced today that its U.S subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has been granted final approval for its Nabumetone tablets, 500 mg and 750 mg strengths from the U.S. Food and Drug Administration.
Lupin’s Nabumetone is the AB-rated generic equivalent of GlaxoSmithKline’s RELAFEN tablets indicated for acute and chronic treatment of the signs and sympto of osteoarthritis and rheumatoid arthritis. Annual sales for the Nabumetone market in the US was $66.8 mn for the twelve months ended September 2010, based on I Health sales data.
No comments:
Post a Comment